• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Excellent lithium ion storage property of porous MnCo2O4 nanorods?
  Peiyuan Zeng,Xiaoxiao Wang,Ming Ye,Qiuyang Ma,Jianwen Li,Wanwan Wang,Baoyou Geng,Zhen Fang RSC Adv., 2016,6, 23074-23084
• 3. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095

Recent Advances in the Study of 5-Amino-3-bromo-4-(difluoromethyl)-2-methylpyridine (CAS: 1804455-37-5)

The compound 5-Amino-3-bromo-4-(difluoromethyl)-2-methylpyridine (CAS: 1804455-37-5) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This heterocyclic compound, characterized by its unique structural features, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, biological activity, and potential as a building block for more complex drug molecules. The presence of both amino and difluoromethyl groups in its structure makes it a valuable candidate for further exploration in drug discovery.

One of the key areas of research has been the optimization of synthetic routes for 5-Amino-3-bromo-4-(difluoromethyl)-2-methylpyridine. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel, high-yield synthesis method that significantly reduces production costs while maintaining high purity. The method involves a multi-step process starting from commercially available precursors, with the bromo and difluoromethyl groups introduced in a controlled manner to ensure regioselectivity. This advancement is expected to facilitate broader adoption of the compound in both academic and industrial settings.

In terms of biological activity, preliminary in vitro studies have demonstrated that 5-Amino-3-bromo-4-(difluoromethyl)-2-methylpyridine exhibits moderate inhibitory effects against certain kinase enzymes implicated in cancer progression. Researchers at a leading pharmaceutical company have incorporated this compound into a series of kinase inhibitors, with some derivatives showing nanomolar potency in cell-based assays. The unique electronic properties conferred by the difluoromethyl group appear to play a crucial role in enhancing binding affinity to target proteins.

Beyond its direct therapeutic potential, this compound has also been investigated as a versatile intermediate in medicinal chemistry. Its reactive amino and bromo groups allow for diverse functionalization, making it a valuable scaffold for structure-activity relationship (SAR) studies. Recent work published in ACS Medicinal Chemistry Letters (2024) highlighted its use in the development of novel antibacterial agents, where modifications to the pyridine core led to compounds with improved activity against drug-resistant bacterial strains.

The physicochemical properties of 5-Amino-3-bromo-4-(difluoromethyl)-2-methylpyridine have also been thoroughly characterized in recent studies. Computational modeling has provided insights into its conformational preferences and electronic structure, which are crucial for understanding its interactions with biological targets. These studies have revealed that the compound exhibits favorable drug-like properties, including good solubility and metabolic stability, further supporting its potential as a lead compound in drug discovery programs.

Looking forward, researchers anticipate that 5-Amino-3-bromo-4-(difluoromethyl)-2-methylpyridine will continue to be an important molecule in chemical biology research. Its unique combination of functional groups and demonstrated biological activity make it a promising candidate for further development. Current efforts are focused on expanding its applications in targeted therapy and exploring its potential in other therapeutic areas such as neurodegenerative diseases and inflammation. As synthetic methodologies continue to improve and our understanding of its biological mechanisms deepens, this compound is likely to play an increasingly significant role in pharmaceutical innovation.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)